Express News | Neurocrine Biosciences Inc - Data Consistent Across All Patient Subgroups in Cahtalyst Study

Reuters58minutes ago

Express News | Neurocrine Biosciences Announces New Results From Exploratory Analyses of the Phase 3 Cahtalyst™ Pediatric Study Demonstrating Crenessity™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

Reuters59minutes ago

Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing

MT Newswires03:29 ET

New Analyst Forecast: $NBIX Given 'Outperform' Rating

Quiver Quantitative20:27 ET

Neurocrine Biosciences(NBIX.US) Director Sells US$3.31 Million in Common Stock

Moomoo News19:07 ET

A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $130 to $190

Moomoo NewsMay 7 09:00 ET · Ratings